A winning stress test strategy has won rare plaudits for management and lit a new fire under the stock.
Senior columnist Adam Feuerstein explains why Ariad Pharmaceuticals is the next big thing in biotech.
Here is this week's roundup of the dumbest actions on Wall Street.
With Apple's new tablet set to hit U.S. stores Friday, the first 'teardown' of the device reveals which component makers are the big iPad winners.
Stocks were barely higher after taking a hit from the latest consumer sentiment report.
JPMorgan equity strategist Thomas Lee argues the sector rebound is just getting started.
Old-fashioned stock picking is giving select mutual funds double the return of the S&P 500.
These stocks are trading below the recent average insider purchase price. If the market grinds lower and pulls these stocks down further, insiders may lend their support once again.
Reports indicate the billionaire investor, who has taken a public stance against banker greed, pays employees compensation competitive with Wall Street awards.
President Obama's decision to file a complaint against China's rare earth export practices could be a slam dunk for companies.